ABSTRACT
BACKGROUND: SAPHO syndrome is recognized as a rare entity with damage to skin and bones due to inflammation. Currently, the treatment for SAPHO syndrome is still a challenge in clinical practice. In this study, an integrated transcriptomics and network pharmacology approach was applied to explore the therapeutic effect and mechanism of Wang-Bi tablet (WBT) on SAPHO syndrome. METHODS: The main components of WBT and their targets, as well as the targets of SAPHO syndrome, were collected from databases. Network visualization was performed using Cytoscape software. The GO and KEGG enrichment analysis was executed by David dataset. Then, the molecular mechanism of WBT improving SAPHO syndrome was validated by transcriptomics of peripheral blood neutrophils in SAPHO syndrome. Finally, the above results were validated by molecular docking. RESULTS: The Network Pharmacology results showed there are 152 core targets for WBT treatment on SAPHO syndrome. RNA-seq data showed 442 differentially expressed genes (DEGs) in peripheral blood neutrophils of SAPHO patients. Intriguingly, NIK/NF-kappaB-, MyD88-dependent toll-like receptor-, and MAPK pathway were included in the enrichment results of network pharmacology and RNA-seq. Moreover, we verified that the core components of WBT have good affinity with the core targets of NIK/NF-kappaB-, MyD88-dependent toll-like receptor-, and MAPK pathway by molecular docking. CONCLUSIONS: This study illustrated that the possible mechanisms of WBT against SAPHO syndrome may be related to NIK/NF-kappaB-, MyD88-dependent toll-like receptor-, and MAPK pathway, and further experiments are needed to prove these predictions.
Subject(s)
Acquired Hyperostosis Syndrome , Drugs, Chinese Herbal , Humans , Acquired Hyperostosis Syndrome/diagnosis , Acquired Hyperostosis Syndrome/drug therapy , Acquired Hyperostosis Syndrome/genetics , NF-kappa B , Molecular Docking Simulation , Myeloid Differentiation Factor 88 , Network Pharmacology , Gene Expression Profiling , Adaptor Proteins, Signal Transducing , Toll-Like ReceptorsABSTRACT
OBJECTIVE: This study aimed to investigate the efficacy and safety of Tripterygium wilfordii Hook F. (TwHF) in the treatment of osteoarticular lesions in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. METHODS: Eligible SAPHO patients were recruited to this single-center trial to receive 12-week TwHF treatment. Two dose groups (1.0-mg/kg/day group and 1.5-mg/kg/day group) were designed and patients were allocated (1:1) to these two groups. The primary endpoint was the change from baseline in Ankylosing Spondylitis Disease Activity Score on the basis of C-reactive protein level (ASDAS) at week 12. RESULTS: All the 30 included patients completed the trial. At week 12, both dose groups showed significant change from baseline in ASDAS (1.0-mg/kg/day group: - 1.34 (1.10), p = 0.000; 1.5-mg/kg/day group: - 1.53 (1.19), p = 0.000). Similar improvement was also found in the Visual Analogue Scale in global osteoarticular pain, Bath Ankylosing Spondylitis Disease Activity Index, and other efficacy measures. The results showed a fast-acting characteristic of TwHF that the maximum efficacy was achieved within the first 2-4 weeks and maintained at a stable level for the rest of the study. No significant differences were observed between the two dose groups under the current sample size. TwHF was well tolerated that no severe adverse events or irregular menstruation were recorded, except for one patient who developed severe alanine aminotransferase elevation at the last follow-up and has stopped the TwHF treatment after the 12-week follow-up. CONCLUSIONS: TwHF should be considered for the treatment of osteoarticular lesions in SAPHO syndrome in clinical practice because of significant efficacy, reliable safety, and high socioeconomic value. TRIAL REGISTRATION: ChiCTR1900025912 Key points ⢠This is the first clinical trial to evaluate Tripterygium wilfordii Hook F. (TwHF) in the treatment of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. ⢠Twelve-week TwHF treatment in both dose groups designed (1.0-mg/kg/day group and 1.5-mg/kg/day group) was well tolerated and could lead to significant disease remission of SAPHO syndrome. ⢠No significant differences were observed between the two dose groups under the current sample size. ⢠TwHF should be considered for the treatment of osteoarticular lesions in SAPHO syndrome in clinical practice because of significant efficacy, reliable safety, and high socioeconomic value.
Subject(s)
Acne Vulgaris , Acquired Hyperostosis Syndrome , Hyperostosis , Osteitis , Synovitis , Acne Vulgaris/drug therapy , Acquired Hyperostosis Syndrome/drug therapy , Female , Humans , Hyperostosis/drug therapy , Osteitis/drug therapy , TripterygiumABSTRACT
is missing (Short Communication).
Subject(s)
Acne Vulgaris , Acquired Hyperostosis Syndrome , Hidradenitis Suppurativa , Acne Vulgaris/diagnosis , Acne Vulgaris/drug therapy , Acquired Hyperostosis Syndrome/diagnosis , Acquired Hyperostosis Syndrome/drug therapy , Biological Therapy , Hidradenitis Suppurativa/diagnosis , Hidradenitis Suppurativa/drug therapy , HumansABSTRACT
Acne fulminans (AF) is a rare and severe form of inflammatory acne presenting clinically with an abrupt outburst of painful, hemorrhagic pustules and ulceration, that may or may not be associated with systemic symptoms, such as fever, polyarthritis, and laboratory abnormalities. It typically affects male teenagers with a pre-existing acne. Although the pathogenetic mechanism has not been established yet, a role of genetic, abnormal immunologic response, drugs intake, hormonal imbalance and viral infection, as causal factors, has been identified. AF may occur as a single disease or may be associated with other disorders. Traditionally, AF has been classified, on the basis of the presence of systemic involvement, in "acne fulminans" and acne fulminans "sine fulminans," when no systemic involvement is present. Recently, four clinical variants have been proposed: acne fulminans with systemic symptoms (AF-SS), acne fulminans without systemic symptoms (AF-WOSS), isotretinoin-induced acne fulminans with systemic symptoms (IIAF-SS), isotretinoin-induced acne fulminans without systemic symptoms (IIAF-WOSS). The diagnosis of AF is usually based on clinical history and physical examination. No specific laboratory abnormalities are generally found. In selected cases, biopsy and/or radiologic imaging are helpful for a correct diagnosis. The treatment significantly differs from severe acne according to severity of clinical presentation and possible systemic involvement. Currently, systemic corticosteroids (prednisolone) and retinoids (isotretinoin) represent the first choice of treatment. Dapsone, cyclosporine A, methotrexate, azathioprine, levamisole, and biological agents such as anakinra, infliximab, adalimumab may be considered as alternative therapies in selected cases. Adjunctive topical and physical therapies may also be considered.
Subject(s)
Acne Vulgaris , Acne Vulgaris/complications , Acne Vulgaris/diagnosis , Acne Vulgaris/physiopathology , Acne Vulgaris/therapy , Acquired Hyperostosis Syndrome/complications , Acquired Hyperostosis Syndrome/diagnosis , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Androgens/adverse effects , Anti-Inflammatory Agents/therapeutic use , Arthralgia/complications , Combined Modality Therapy , Debridement , Dermatologic Agents/therapeutic use , Diagnosis, Differential , Disease Progression , Female , Humans , Immunosuppressive Agents/therapeutic use , Inflammation , Isotretinoin/adverse effects , Isotretinoin/therapeutic use , Lasers, Dye , Low-Level Light Therapy , Male , Photochemotherapy , Propionibacteriaceae/immunology , Retinoids/therapeutic use , Symptom Assessment , Young AdultABSTRACT
RATIONALE: Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare disease without standard treatments. Tripterygium wilfordii hook f (TwHF) is a traditional Chinese herb with anti-inflammatory effect, and 1.0âmg/(kg·d) dose of Tripterygium glycosides has been reported to significantly improve the disease activity of a SAPHO patient in a case report. However, the optimal dose of TwHF is still unclear. Here, we report the first case of SAPHO patient who achieved rapid remission in clinical symptoms after receiving 1.5âmg/(kg·d) dose of Tripterygium glycosides treatment. PATIENT CONCERNS: A 67-year-old woman noted palmoplantar pustulosis and pain in the anterior chest wall and waist. Bone scintigraphy demonstrated the typical tracer accumulation feature and magnetic resonance images showed bone marrow edema in lumbosacral vertebra. DIAGNOSES: The diagnosis was made by dermatological and osteoarticular manifestations and classical signs in bone scintigraphy in accordance with the diagnostic criteria proposed in 2012. INTERVENTIONS: Tripterygium glycosides was given with a primary dose of 1.5âmg/(kg·d) for 1 month and then reduced at a rate of 10âmg every 2 weeks until 1.0âmg/(kg·d) for a long-term maintenance. OUTCOMES: Fast-induced remission on clinical manifestations was achieved and magnetic resonance imaging abnormality was improved significantly. Additionally, no apparent side effects were observed. LESSONS: 1.5âmg/(kg·d) dose of Tripterygium glycosides seems to have fast-induced remission than 1.0âmg/(kg·d) with reliable safety. Besides, Tripterygium glycosides may also have a pharmacological effect of inhibiting osteolysis and enhancing bone strength.
Subject(s)
Acquired Hyperostosis Syndrome/drug therapy , Bone and Bones/pathology , Drugs, Chinese Herbal/therapeutic use , Glycosides/therapeutic use , Acquired Hyperostosis Syndrome/pathology , Aged , Bone and Bones/diagnostic imaging , Bone and Bones/drug effects , Drugs, Chinese Herbal/administration & dosage , Female , Glycosides/administration & dosage , Humans , Lumbosacral Region/diagnostic imaging , Lumbosacral Region/pathology , Magnetic Resonance Imaging/methods , Osteolysis/prevention & control , Psoriasis/etiology , Radionuclide Imaging/methods , Remission Induction , Treatment Outcome , TripterygiumABSTRACT
OBJECTIVE: To further characterize clinical characteristics, etiologic factors, associated disorders, and treatment of palmoplantar pustulosis (PPP). PATIENTS AND METHODS: We conducted a retrospective review of patients with PPP at Mayo Clinic between January 1, 1996, and December 31, 2013. RESULTS: Of 215 patients with PPP identified, 179 (83%) were female, and the mean age at onset was 45.3 years. Most patients (n=165, 77%) were current or former smokers. At diagnosis, 15 patients (7%) had an anxiety diagnosis and 9 (4%) had an infection. Nineteen cases (9%) were drug induced. Comorbid conditions included thyroid disease in 18 patients (8%), gluten sensitivity in 3 (1%), and type 2 diabetes mellitus in 21 (10%). In all, 194 patients (90%) received topical corticosteroids, 55 (26%) received phototherapy, and 54 (25%) received systemic agents. CONCLUSION: More than three-fourths of the patients in this study had a history of smoking, which is considered a triggering or aggravating factor for PPP. Regarding comorbid conditions, gluten sensitivity and thyroid disease were found less frequently than previously reported in the literature. Treatment regimens and responses in this cohort varied considerably.
Subject(s)
Focal Infection/epidemiology , Psoriasis , Smoking/epidemiology , Stress, Psychological/epidemiology , Tumor Necrosis Factor-alpha/adverse effects , Acquired Hyperostosis Syndrome/epidemiology , Administration, Topical , Adrenal Cortex Hormones/administration & dosage , Adult , Age of Onset , Comorbidity , Diabetes Mellitus, Type 2/epidemiology , Female , Focal Infection/complications , Food Hypersensitivity/epidemiology , Glutens/adverse effects , Glutens/immunology , Humans , Male , Middle Aged , Minnesota/epidemiology , Phototherapy , Psoriasis/diagnosis , Psoriasis/epidemiology , Psoriasis/etiology , Psoriasis/therapy , Retrospective Studies , Sex Distribution , Smoking/adverse effects , Stress, Psychological/complications , Thyroid Diseases/epidemiology , Tumor Necrosis Factor-alpha/therapeutic use , Young AdultABSTRACT
Objective To evaluate the clinical efficacy and safety of Modified Chaihu Guizhi De- coction on SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. Methods Totally 40 patients with SAPHO syndrome were randomized to the treatment group(20 cases) and control group(20 cases). The treatment group was treated with Modified Chaihu Guizhi Decoction, and the control group with alendronate sodium 70 mg each week. The therapeutic course for all was 12 weeks. The Visual Analogue Scale (VAS) pain scores, bath ankylosing spondylitis activity index (BASDAI) , bath ankylosing spondylitis functional index(BASFI) , erythrocyte sedimentation rate(ESR) and hypersensitivity C reactive protein (hs-CRP) were measured before and after treatment. Adverse events were observed. Results The VAS, BASDAI, and BASFI score significantly improved compared with baseline in the treatment group (P <0. 01 , P <0. 05). The VAS and BASDAI score of the treatment group improved compared with the control group after treatment (P <0. 05). Three patients in the control group reported adverse events with digestive tract symptoms, while there was no obvious adverse drug reactions in the treatment group. Conclusions Modified Chaihu Guizhi Decoction was superior to alendronate sodium in the treat- ment of SAPHO syndrome without obvious adverse drug reactions.
Subject(s)
Acquired Hyperostosis Syndrome , Drugs, Chinese Herbal , Acquired Hyperostosis Syndrome/drug therapy , Blood Sedimentation , Drugs, Chinese Herbal/therapeutic use , Humans , Severity of Illness Index , Spondylitis, AnkylosingABSTRACT
RATIONALE: SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome is an autoinflammatory disease with no standardized treatment. Tripterygium wilfordii hook f (TwHF) is a Chinese herb with immunosuppressive effects and has been used to treat some chronic inflammatory diseases. However, it has not been reported as a therapeutic option in SAPHO syndrome. Here we present the first report in which a remarkable remission of SAPHO syndrome was achieved in response to TwHF. PATIENT CONCERNS: A 57-year-old female patient noted swelling and pain at the anterior chest wall and scattered rashes like psoriasis vulgaris. Bone scintigraphy demonstrated the classic "bull's head" sign and magnetic resonance images indicated bone marrow edema on T5. DIAGNOSES: The diagnosis was made by dermatological and osteoarticular manifestations and classical "bull's head" sign in bone scintigraphy. INTERVENTIONS: TwHF with a priming dose of 20âmg 3 times per day and a gradual dose reduction of 20âmg per day in every 3 months. Four months later, methotrexate was added with 10âmg per week. OUTCOMES: Osteoarticular symptoms and radiological abnormalities were improved dramatically. LESSONS: This case illustrates a promising strategy to treat SAPHO syndrome.
Subject(s)
Acquired Hyperostosis Syndrome/drug therapy , Drugs, Chinese Herbal/therapeutic use , Tripterygium , Female , Humans , Middle Aged , Remission Induction/methods , Treatment OutcomeSubject(s)
Acquired Hyperostosis Syndrome/therapy , Combined Modality Therapy , Humans , Integrative Medicine , Male , Middle AgedABSTRACT
During the past years, significant progress in the understanding of the complexity, regulation, and relevance of innate immune responses underlying several inflammatory conditions with neutrophilic skin involvement has been made. These diseases belong to the novel class of autoinflammatory diseases, and several are caused by mutations in genes regulating the function of innate immune complexes, termed inflammasomes, leading to enhanced secretion of the proinflammatory cytokine IL-1ß. Consequently, targeting of IL-1ß has proven successful in the treatment of these diseases, and the identification of related pathogenic mechanisms in other more common skin diseases characterized by autoinflammation and neutrophilic tissue damage also provides extended opportunities for therapy by interfering with IL-1 signaling.
Subject(s)
Autoimmune Diseases/immunology , Biological Therapy , Inflammasomes/immunology , Keratinocytes/immunology , Skin Diseases/immunology , Acne Vulgaris/genetics , Acne Vulgaris/immunology , Acne Vulgaris/therapy , Acquired Hyperostosis Syndrome/genetics , Acquired Hyperostosis Syndrome/immunology , Acquired Hyperostosis Syndrome/therapy , Animals , Arthritis, Infectious/genetics , Arthritis, Infectious/immunology , Arthritis, Infectious/therapy , Autoimmune Diseases/genetics , Autoimmune Diseases/therapy , Humans , Inflammasomes/genetics , Mice , Pyoderma Gangrenosum/genetics , Pyoderma Gangrenosum/immunology , Pyoderma Gangrenosum/therapy , Schnitzler Syndrome/genetics , Schnitzler Syndrome/immunology , Schnitzler Syndrome/therapy , Skin Diseases/genetics , Skin Diseases/therapyABSTRACT
OBJECTIVE: To date there is no uniformly effective treatment for either chronic recurrent multifocal osteomyelitis (CRMO) or synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome. We report on our clinical experience of using biologic therapy to treat children with these conditions. METHODS: Retrospective descriptive case series of four children with refractory disease treated with biologics. Disease activity was assessed at predetermined time points (T = 0, T = 6 weeks and T = 12 months after the start of biologic therapy, and at latest follow-up) using a combination of clinical examination and radiological findings: a 10 cm pain and physician visual analogue scale; the Childhood Health Assessment Questionnaire as an assessment of disability; and changes in markers of systemic inflammation. RESULTS: There was an initial improvement in all parameters assessed for all three children treated with TNF-alpha blockade, although the third case had to discontinue the therapy due to a suspected (but unconfirmed) fungal skin infection. Anakinra treatment alleviated the symptoms in the fourth patient at 6 weeks, but there was no sustained response to treatment at 1-year follow-up. CONCLUSION: We present our preliminary experience of using biological therapies to treat children with CRMO and SAPHO in conjunction with other immunosuppression. Further studies are needed to establish the role of these therapies in refractory CRMO and SAPHO.
Subject(s)
Acquired Hyperostosis Syndrome/drug therapy , Antirheumatic Agents/therapeutic use , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Osteomyelitis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Acquired Hyperostosis Syndrome/physiopathology , Biological Therapy/methods , Child , Chronic Disease , Humans , Infant , Osteomyelitis/physiopathology , Retrospective Studies , Treatment Outcome , Tumor Necrosis Factor-alpha/therapeutic useABSTRACT
Acne is the most common disease of the skin. It affects 85% of teenagers, 42.5% of men, and 50.9% of women between the ages of 20 and 30 years.96,97 The role of hormones, particularly as a trigger of sebum production and sebaceous growth and differentiation, is well known. Excess production of hormones, specifically androgens, GH, IGF-1, insulin, CRH, and glucocorticoids, is associated with increased rates of acne development. Acne may be a feature in many endocrine disorders, including polycystic ovary disease, Cushing syndrome, CAH, androgen-secreting tumors, and acromegaly. Other nonendocrine diseases associated with acne include Apert syndrome, SAPHO syndrome, Behçet syndrome and PAPA syndrome. Acne medicamentosa is the development of acne vulgaris or an acneiform eruption with the use of certain medications. These medications include testosterone, progesterone,steroids, lithium, phenytoin, isoniazid, vitamins B2, B6, and B12, halogens, and epidermal growth factor inhibitors. Management of acne medicamentosa includes standard acne therapy. Discontinuation of the offending drug may be necessary in recalcitrant cases. Basic therapeutic interventions for acne include topical therapy, systemic antibiotics,hormonal agents, isotretinoin, and physical treatments. Generally, the severity of acne lesions determines the type of acne regimen necessary. The emergence of drug-resistant P acnes and adverse side effects are current limitations to effective acne management.
Subject(s)
Acne Vulgaris/etiology , Acne Vulgaris/therapy , Acne Vulgaris/metabolism , Acquired Hyperostosis Syndrome/complications , Acrocephalosyndactylia/complications , Anti-Bacterial Agents/therapeutic use , Behcet Syndrome/complications , Dermatologic Agents/therapeutic use , Drug-Related Side Effects and Adverse Reactions , Endocrine System Diseases/complications , Hormones/biosynthesis , Hormones/therapeutic use , Humans , Isotretinoin/therapeutic use , Low-Level Light Therapy , PhototherapyABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Acquired Hyperostosis Syndrome/diagnosis , PUVA Therapy , Adrenal Cortex Hormones/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic useABSTRACT
INTRODUCTION: Primary chronic osteomyelitis of the jaw is a rare, non-suppurative, chronic inflammatory disease of unknown aetiology. To date, classification is confusing due to a non-uniform terminology. The aim of this study was to establish a simple (clinical) classification based on patient data from our clinic. METHODS: Retrospective analysis revealed 30 cases of which clinical course, radiology, pathology, therapy and outcome were analysed. RESULTS: Both sexes were equally represented. The mean age at onset of disease was 35 years (range 5-76 years). Onset of disease revealed two peaks of incidence, one in adolescence and one after age 50 years. While clinical symptoms were similar in all cases, an increased intensity of these symptoms was noted in younger individuals as well as in the early stages of the disease. Five adults and one adolescent presented with additional non facial bone, joint and skin manifestations consistent with the diagnosis of SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome, or chronic recurrent multifocal osteomyelitis. Radiology demonstrated sclerosis, osteolysis and periosteal reaction in variable stages in all cases. However, findings were more extensive in younger patients. Histology revealed different stages of chronic inflammation in all cases. Microabscess formation was noted in 11 cases, six of which were children/adolescents. Therapy consisted mainly of surgery, antibiotics and hyperbaric oxygen therapy. At the end of the follow up period, 11 patients demonstrated complete remission, while in 14 cases amelioration and in 5 no significant improvement was noted. CONCLUSION: Based on differences in age at presentation, clinical appearance and course, radiology and histology, a subclassification into early and adult onset primary chronic osteomyelitis has been established. Cases with purely mandibular involvement should further be distinguished from cases associated with other syndromes.